Skip to content

IFGL Refractories Limited

IFGL Refractories Limited has informed the Exchange about Allotment of Bonus Equity Shares. |SUBJECT: General Updates

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint. |SUBJECT: Press Release

Exit mobile version